James Noble
Vorsitzender bei OREXO AB
Vermögen: 43 113 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| John Bell | M | 71 |
Avidex Ltd.
 Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | 9 Jahre |
| Helena Tayton-Martin | M | 57 |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | 16 Jahre |
| Nick la Thangue | M | - |
Celleron Therapeutics Ltd.
 Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.
Ingenox Therapeutics Ltd.
 Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
| David Kerr | M | - |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
| Nikolaj Sørensen | M | 52 | 13 Jahre | |
| Adrian Rawcliffe | M | 52 | 9 Jahre | |
| Elliot Norry | M | 61 | 9 Jahre | |
| Volker Knappertz | M | 59 |
Sutura Therapeutics Ltd.
 Sutura Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021. | 7 Jahre |
| Thomas Engelen | M | 66 |
Pneumagen Ltd.
 Pneumagen Ltd. BiotechnologyHealth Technology Pneumagen Ltd. is engaged in biotechnology services. The company was founded in 2016 and is headquartered in Fife, the United Kingdom.
Pneumagen (Holdings) Ltd.
| - |
| Declan Doogan | M | 72 |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | - |
| Stephen Allen Hurly | M | 56 | 5 Jahre | |
| David Mott | M | 58 | 10 Jahre | |
| Staffan Lindstrand | M | 62 | 22 Jahre | |
| Charlotte Hansson | F | 55 | 4 Jahre | |
| Nick Dixon-Clegg | M | - |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
| Joanna Brewer | M | 47 | 15 Jahre | |
| Amy Garabedian | F | - | 3 Jahre | |
| Collette Coll | M | - |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
| Simon Kerry | M | 61 |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
| Mary Pat Christie | F | 61 | 5 Jahre | |
| Peter Kiener | M | 72 |
University of Oxford
| 5 Jahre |
| Christine Rankin | F | 60 | 2 Jahre | |
| Lena Wange | F | - | 8 Jahre | |
| Iain Ward | M | - | 3 Jahre | |
| Karen Wilson | F | 61 | 3 Jahre | |
| George Frederick Wilkinson | M | 68 | 5 Jahre | |
| Lawrence Alleva | M | 74 | 9 Jahre | |
| Edwin Wagena | M | - |
Sutura Therapeutics Ltd.
Sutura Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021. | 3 Jahre |
| Bill Fleming | M | - |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
| Ali Behbahani | M | 47 | 10 Jahre | |
| John Furey | M | 59 | 6 Jahre | |
| John Beadle | M | - |
Pneumagen (Holdings) Ltd.
Pneumagen Ltd.
Pneumagen Ltd. BiotechnologyHealth Technology Pneumagen Ltd. is engaged in biotechnology services. The company was founded in 2016 and is headquartered in Fife, the United Kingdom. | 2 Jahre |
| Jessica Truscello | F | - | 3 Jahre | |
| Garry Menzel | M | 59 | 1 Jahre | |
| Hans van der Vliet | M | 50 | 7 Jahre | |
| Peter Ros | M | 52 | 4 Jahre | |
| Paul W. H. I. Parren | M | 60 | 6 Jahre | |
| Wouter van Hunnik | M | - | 3 Jahre | |
| Adrian Campbell | M | 58 | 3 Jahre | |
| Edward Kim | M | - | 2 Jahre | |
| Sharp Kerry | F | - | 9 Jahre | |
| Douglas Thomson | M | 60 |
Pneumagen (Holdings) Ltd.
| - |
| Richard Taylor | M | - |
Ingenox Therapeutics Ltd.
Ingenox Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue. | - |
| Mark R. Bamforth | M | 61 |
Pneumagen (Holdings) Ltd.
| - |
| Richard Taylor | M | - |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | - |
| Garry Taylor | M | - |
Pneumagen Ltd.
Pneumagen Ltd. BiotechnologyHealth Technology Pneumagen Ltd. is engaged in biotechnology services. The company was founded in 2016 and is headquartered in Fife, the United Kingdom. | - |
| Kapil Dhingra | M | 64 | 3 Jahre | |
| John Lunger | M | 55 | 7 Jahre | |
| Mary Wadlinger | F | 64 | 1 Jahre | |
| Gavin Wood | M | 54 | 4 Jahre | |
| Ton Adang | M | 63 | 7 Jahre | |
| William Bertrand | M | 59 | 7 Jahre | |
| Thomas Hanke | M | - |
Sutura Therapeutics Ltd.
Sutura Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021. | - |
| Douglas Thomson | M | - |
Pneumagen Ltd.
Pneumagen Ltd. BiotechnologyHealth Technology Pneumagen Ltd. is engaged in biotechnology services. The company was founded in 2016 and is headquartered in Fife, the United Kingdom. | - |
| Sangwoon Lee | M | - |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | - |
| Andrew Allen | M | 57 | 1 Jahre | |
| Fredrik Järrsten | M | 57 | 2 Jahre | |
| Priti Hegde | M | 52 | 1 Jahre | |
| Robin Evers | M | - | 1 Jahre | |
| Sangwoo Lee | M | 52 |
Celleron Therapeutics Ltd.
Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | 8 Jahre |
| Juli P. Miller | M | - | 8 Jahre | |
| Cecilia Coupland | F | 48 | 5 Jahre | |
| Robert Rönn | M | 48 | 7 Jahre | |
| Garry Taylor | M | 70 |
Pneumagen (Holdings) Ltd.
| - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Adam George | M | 54 | 13 Jahre | |
| J. Kenneth Charles Knowles | M | 77 | 1 Jahre | |
| Erik van den Berg | M | 51 | 6 Jahre | |
| Graham Robert Lay | M | 74 | 4 Jahre | |
| Scott Giacobello | M | 54 | 4 Jahre | |
| Michael Robert Evans | M | 66 |
University of Oxford
| 7 Jahre |
| W. Edward Alastair Morrison | M | 66 |
University of Oxford
| 6 Jahre |
| David Wallace Ballintine Snow | M | 63 | 1 Jahre | |
| Eliot Forster | M | 58 | 3 Jahre | |
| David Morrison | M | 65 |
University of Oxford
| 3 Jahre |
| John Thornton | M | 70 |
University of Oxford
| 4 Jahre |
| Eva-Lotta Allan | F | 65 | 5 Jahre | |
| Daniel Kapi | M | - |
University of Oxford
| 6 Jahre |
| Ka Shuen Wen | M | 70 |
University of Oxford
| 8 Jahre |
| Michael Matly | M | 42 | - | |
| Davide Giacomo Federico Benello | M | 70 |
University of Oxford
| 4 Jahre |
| Yannis Stournaras | M | 67 |
University of Oxford
| 3 Jahre |
| Stephen Wright | M | 71 | 13 Jahre | |
| Alf Gunnar Martin Nicklasson | M | 69 | 8 Jahre | |
| Charles Sigal | M | 72 | 8 Jahre | |
| Harry Small | M | - |
University of Oxford
| 6 Jahre |
| Henrik Rasmussen | M | 65 | 5 Jahre | |
| Larry Ellberger | M | 76 |
Powderject Pharmaceuticals Plc
 Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | 6 Jahre |
| Geoffrey Guy | M | 70 | 23 Jahre | |
| Justin Gover | M | 53 | 22 Jahre | |
| David Kirk | M | 70 | 11 Jahre | |
| Jonathan Michael Laughton | M | - | 7 Jahre | |
| Richard D. Forrest | M | 75 | - | |
| Stephen Julius | M | 65 |
University of Oxford
| 4 Jahre |
| Maria Christina Schauman | F | 59 | 8 Jahre | |
| Oliver Charles Hewardine Cooke | M | 70 | 3 Jahre | |
| Timothy Edwards | M | 68 | 6 Jahre | |
| Peter Jones | M | 67 |
University of Oxford
| 3 Jahre |
| Neill Moray MacKenzie | M | - |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | 6 Jahre |
| Jackie Sheppard | F | 68 |
University of Oxford
| 5 Jahre |
| Henrik Kjaer Hansen | M | 48 | 5 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigtes Königreich | 72 | 72,00% |
| Schweden | 16 | 16,00% |
| Niederlande | 13 | 13,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- James Noble
- Persönliches Netzwerk
